Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 13/20 | 0.46 |
| ▸ | CTSS | P25774 | 2/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8021226 | 0.96 | CTSK (0.51) | CTSKCTSSAAK1KMT2ACTSL | |
| SCHEMBL7381049 | 0.96 | CTSK (0.51) | CTSKCTSSAAK1KMT2ACTSL | |
| SCHEMBL10270440 | 0.95 | CTSK (0.48) | CTSKCTSSAAK1KMT2ACA1 | |
| SCHEMBL9102877 | 0.88 | CTSK (0.50) | CTSKCTSSAAK1KMT2ACTSL | |
| SCHEMBL9102886 | 0.88 | CTSK (0.50) | CTSKCTSSAAK1KMT2ACTSL | |
| SCHEMBL7376384 | 0.85 | CTSK (0.48) | CTSKCTSSAAK1CTSLCTSB | |
| SCHEMBL9741659 | 0.85 | CTSK (0.48) | CTSKCTSSAAK1CTSLCTSB | |
| SCHEMBL9741664 | 0.85 | CTSK (0.48) | CTSKCTSSAAK1CTSLCTSB | |
| SCHEMBL7295848 | 0.85 | CTSK (0.48) | CTSKCTSSAAK1CTSLCTSB | |
| SCHEMBL9104071 | 0.84 | CTSK (0.55) | CTSKCTSSAAK1KMT2ACTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142668-A1 | CATHEPSIN C INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142668-A1 | CATHEPSIN C INHIBITORS | CTSE, CTSB, CTSS | CTSK 8/4885CTSS 3/4885AAK1 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.